Climb Bio GAAP EPS of -$0.13

2 hours ago 1

Climb Bio press release (NASDAQ:CLYM): Q2 GAAP EPS of -$0.13.
Cash, cash equivalents and marketable securities were $187.4 million as of June 30.
Cash, cash equivalents and marketable securities are expected to fund operations through 2027.
Other income, net was $2.0 million for the three months ended June 30, 2025, compared to $1.5 for the comparable period in 2024.

Recommended For You